Beyeonics Surgical Notes Dr. Sharon Bakalash Appointed CMO Effective October 1, 2020

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

December 22, 2020

Beyeonics Surgical announced Dr. Sharon Bakalash was appointed chief medical officer effective October 1, 2020.

Beyeonics Surgical notes Dr. Sharon Bakalsh is a seasoned biotechnology entrepreneur and an ophthalmic surgeon with more than two decades of demonstrated leadership in business, science, and medicine. Before stepping in as Beyeonics Surgical CMO, she had worked with the company as a consultant for nearly 4 years.

As the founder of SB Strategic Development Consultants Group, she provided clinical development, strategic planning, and business development guidance to Beyeonics, as well as with other start-up companies, venture funds and global pharma companies- spanning the pharmaceutical, drug delivery and surgical device arenas.

Dr. Bakalash had served in various roles of exceeding responsibilities within the pharmaceutical industry.  In her last role within Novartis, she was responsible for the US early development portfolio in both Ophthalmology and ENT—forming development strategies, enabling pipeline enrichment stemming for both external and internal innovation.  Prior to that, she headed business development at Alcon, where she was evaluated, negotiated, and oversaw numerous transactions- spanning acquisitions, joint ventures, and a wide variety of co- development frameworks.

Prior to Novartis, Dr. Bakalash was a part of the Harvard University Office of Technology Development, out-licensing innovations stemming from the medical school.

Dr. Bakalash holds an MD from Ben Gurion University, a PhD in Neuroimmunology from the Weizmann Institute of Science, and a business degree from Northeastern University. Dr. Bakalash has also completed a post-doctoral fellowship at Harvard University.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.